BioSpaceOriginal article
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
RegulatoryPositive
AI Analysis
Summary
FDA extends its review of Capricor's Duchenne muscular dystrophy cell therapy while Merck and Moderna report positive data for their mRNA-based cancer vaccine; Eli Lilly and Novo Nordisk compete in the oral obesity market as Trump nominates a new FDA commissioner.
Outcome Details
FDA extends review of Capricor's DMD cell therapy
Importance:6/10
Sentiment:
0.30
FDA review extensionDMD therapymRNA cancer vaccineobesity marketFDA commissioner nomination
Read the original article
Published by BioSpace on August 26, 2026 10:24 AM